Zydus Cadila succesfully launched in India Turbospin licensed by PH&T

August 2010   For the launch of the product in the asthma market, Zydus  conducted a total of 75 meeting with Chest clinicians from May to August plus over 450  Spirometry camps for patient screening. The result is that Indian doctors have appreciated the concept of Turbospin which enables simple and easy inhalation. The ease of inhaling and carrying the device is highly appreciated by the patients too.

Zydus Cadila, one of the top five pharma companies in India, is an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products.  Over 50 million people in Central and Southern Asia have asthma , according to  The Global Burden of Asthma Report 2007. Due to rapid industrialization and urbanization throughout the region, the prevalence of asthma is predicted to increase rapidly in the coming years. The increase is likely to be particularly dramatic in India, which is projected to become the world's most populous nation by 2050. An absolute 2% increase in the prevalence of asthma in India would result in an additional 20 million people with the disease. Although asthma cannot be cured, effective medications to treat and manage the disease exist. One of the authors of the Global Burden of Asthma Report, Professor Richard Beasley, of the Medical Research Institute of New Zealand, says, "In Central and Southern Asia, effective asthma management is often limited by lack of availability or affordability of medications." In some areas widespread misconceptions about asthma and its treatment, and reluctance of patients to use the inhaler devices that are key to effective delivery of asthma medicines, also pose challenges. Turbospin device will be used with the following capsules: Formonide (budesonide+formoterol), Forair (salmeterol+fluticasone),Tiomist (tiotropium bromide), Formosone (folmoterol fumarate ) , Tioform (tiotropium bromide+folmoterol fumarate).